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issued by CDR, 143 were negative and INESSS agreed with CDR in 90% of these 
recommendations. 132 of CDR’s recommendations were negative, of which INESSS 
agreed in 48% of cases. ConClusions: INESSS has a higher positive recommen-
dation rate and, possibly due to the broader scope for funding recommendations, 
frequently disagrees with CDR’s analysis, particularly when CDR’s recommenda-
tion is negative.
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objeCtives: Countries already have a long history of referencing each other on 
drug prices through International price Referencing. However it is still unclear 
whether a similar kind of referencing exists for overall market access decisions. 
The objective of this report is 3 fold: first to identify if decision referencing exists 
between these countries and if yes how. Secondly to understand the extent of 
influence one country might have over another, and thirdly whether this process 
is formal or informal. Methods: The research was conducted through in-depth 
secondary research and interviews with stakeholders in 14 countries including the 
UK, Ireland, Germany, France, Spain, Portugal, Italy, Sweden, Canada, Australia, The 
Netherlands, Austria, Hungary and Poland Results: NICE (UK), SMC (Scotland), 
and AWMSG (Wales) represent the more sophisticated attempts to integrate HTA 
into the decision-making process and are currently the most influential HTAs in 
the world with over 60 countries referencing them worldwide. IQWiG (Germany), 
HAS (France), TLV (Sweden), and HSE (Ireland) form the medium influence HTA 
agencies. This can be attributed to the fact that these agencies have their own 
unique approach to HTA. These agencies consider clinical effectiveness and 
comparator studies over cost effectiveness models. Poland, Spain, Italy, Austria, 
Hungary, and Portugal form the low influence HTA agencies that capitalize on the 
lessons learned from more established international HTA systems due to lack of 
in-house qualified personnel and resources for HTA activities. ConClusions: The 
research indicated that there is definitely a cross-influence influence of market 
access decisions between countries across geographies. Decisions are referenced 
informally, via direct contact with other HTA agencies, through international net-
working platforms like EUnetHTA, and INAHTA, or accessing published assess-
ment reports. Variance in the level of influence can be attributed to the age and 
maturity of the HTA, and longevity of assessment performed (specifically cost-
effectiveness assessment).
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objeCtives: The Pharmacoeconomics allows economic evaluation of products and 
services for health and helps a lot the health care decision-making. Therefore, there 
is a need for training of human resources with solid knowledge in pharmacoeco-
nomics in Brazil. However, little is known to what extent Pharmacoeconomics is 
taught in schools of pharmacy in Brazil. The objective of this study was to survey the 
pharmacy schools in Brazil to determine the extent of education in pharmacoeco-
nomics offered during the school year 2012-2013. Methods: A questionnaire based 
on previous studies [Rascati (1998, 2005, 2013) was developed. This was emailed to 
55 pharmacy schools in Brazil during October and December 2013. The schools were 
selected from the Ministry of Education website. University schools of public and pri-
vate (only those that have high concepts in the National Examination Performance 
of Students) were included. In addition, a search was made in the database direc-
tories of research groups from National Council for Scientific and Technological 
Development (CNPq). Results: Results of the questionnaires sent 55, 14 went 
unanswered. Only one school does not address the teaching of Pharmacoeconomics 
in no time. Most discuss some concepts within various disciplines (see 8:0). Four 
schools have formal disciplines that teach only Pharmacoeconomics or health 
technology assessment (more than 30 hours). All agree that the education of 
pharmacoeconomics is important. In the search for directories of research groups 
were found 23 groups that develop research in the area of Pharmacoeconomics in 
Brazil. ConClusions: Pharmacoeconomics education in Brazil is still in its infancy 
and there is a unique opportunity for well-trained instructors and researchers to 
fill this gap. Provide an education in Pharmacoeconomics to pharmacy and econo-
mists students is especially important in the context of evidence-based decisions 
and when health issues and allocation of scarce resources is a priority for Brazilian 
Health System.
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objeCtives: The nature and frequency of global stakeholder real world data 
(RWD) “ask” is growing and there is an impact of not having RW evidence upon 
market entry such as delayed approval, suboptimal reimbursement and unfavora-
ble re-evaluation. We aimed to assess RWD use for market access (MA) decisions in 
key global markets. Methods: Search of the HTAWatch database supplemented 
by an online search of MA stakeholders in the US, UK, Australia, and Canada 
for use of RWD to support of initial assessment, re-evaluation or coverage and 
reimbursement recommendations. Use of RWD included safety, effectiveness, 
economic or quality of life studies. We also assessed theevidence level required 
from registry to provider or patient survey data. Results: In the UK, the National 
Health Service uses real-world adherence studies to update national treatment 
guidelines and inform reimbursement. In Australia, the Pharmaceutical Benefits 
Advisory Committee is willing to delay or make temporary decisions in anticipa-
tion of RWD on a product’s clinical effectiveness or economic value message. The 
PHP106
exPlorIng tHe VarIaBIlIty BetWeen dISeaSe tyPe and tHe ProPortIon 
of SuBmISSIonS WItH IcerS HIgHer tHan tHe tHreSHold tHat are 
accePted By Hta agencIeS
Griffiths E.A., Walsh S.C.M.
HERON – A PAREXEL Company, London, UK
objeCtives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £30,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To inform future submissions, we explored the 
proportion of accepted submissions by disease area and examined any variability in 
the proportion of submissions that were accepted despite the reported ICERs being 
higher than these thresholds. Methods: All HTA appraisals from January 2000 
to January 2014 from NICE, SMC, CADTH, and PBAC were included in the analysis. 
Multiple technology appraisals, vaccination programmes, requests for advice, and 
submissions for which an ICER could not be determined were excluded from analy-
sis. Appraisals were categorized by BNF disease type and the full responses were 
reviewed; the submitted ICER, recommendation, and reasoning behind the recom-
mendation were extracted. Results: Across all four agencies, 679 submissions 
met the inclusion criteria and 218 submissions included a higher than threshold 
ICER, with 62 (28%) of these accepted. The proportion of submissions with ICERs 
above the threshold that were accepted varied by disease type, ranging from 0% 
(Cardiovascular System) to 50% (Skin). This variability was largely due to the low 
number of submissions with ICERs above the threshold in 14/15 disease type cat-
egories. The remaining disease type (Malignant Disease and Immunosuppression) 
accounted for the majority (59%) of all submissions with ICERs higher than the 
threshold; 36/128 (28%) of these were accepted. Key decision drivers for acceptance 
included unmet clinical need, and condition of participation in a patient access 
or risk sharing scheme. ConClusions: A considerable proportion of submis-
sions were accepted despite ICERs above the threshold, but this proportion varied 
widely between disease types. The majority of disease types had few submissions 
reporting ICERs above the threshold, with the exception of Malignant Disease and 
Immunosuppression.
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objeCtives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £30,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To inform future submissions, we explored the 
proportion of rejected submissions by disease area and examined any variability in 
the proportion of submissions that were rejected despite the reported ICERs being 
lower than these thresholds Methods: All HTA appraisals from January 2000 to 
January 2014 from NICE, SMC, CADTH, and PBAC were included in the analysis. 
Multiple technology appraisals, vaccination programmes, requests for advice, and 
submissions for which an ICER could not be determined were excluded from analy-
sis. Appraisals were categorized by BNF disease type and the full responses were 
reviewed, with the submitted ICER, recommendation, and reasoning behind the 
recommendation extracted. Results: Across all four agencies, 679 submissions 
met the inclusion criteria and 405 submissions included a lower than threshold 
ICER, with 126 (31%) of these submissions rejected. The proportion of submissions 
rejected despite ICERs below the threshold varied by disease type. Disease types 
where a high proportion (≥ 50%) of submissions were rejected despite ICERs below 
the threshold included ‘Respiratory System’ (55% rejected), ‘Central Nervous System’ 
(55%), and ‘Nutrition and Blood’ (55%). Disease areas with a low proportion (≤ 20%) 
of rejected submissions were ‘Infections’ (19%) and ‘Eye’ (20%). Key decision drivers 
for rejection these disease types were due to high levels of uncertainty regarding 
clinical-effectiveness, and subsequent cost-effectiveness. ConClusions: The 
proportion of submissions that were rejected varied dramatically by disease type. 
In some disease types over half of submissions with an ICER below the threshold 
were not recommended largely due to non-robust economic analyses, which may 
indicate inherent underlying difficulties in these disease types in submitting a 
conclusive data package.
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objeCtives: To compare the positive recommendation rate and agreement 
between CDR and INESSS. Methods: In Canada, eligible non-cancer prescription 
drugs approved by Health Canada are reviewed by 2 health technology assess-
ment (HTA) agencies: the Common Drug Review (CDR) and the Institute national 
d’excellence en santé et en services sociaux (INESSS). CDR is part of the Canadian 
Agency for Drugs and Technologies in Health (CADTH), which makes reimburse-
ment recommendations that are considered by provincial and federal plans, with 
the exception of Quebec, in making their formulary coverage decisions. In Quebec 
INESSS performs HTA and issues recommendations to the Regie d’assurance mala-
die Quebec (RAMQ). Prior to INESSS, HTA in Quebec was performed by the Conseil 
du Médicaments (CdM). Using our proprietary CDR Tracker®database we examined 
the recommendations by both agencies and compared recommendation positivity 
and congruence for all drugs which have been reviewed by CDR, up to December 
31, 2013. We separately considered positive and negative recommendations by 
both agencies. Results: The overall positivity rate for CDR recommendations in 
this period was 52%, compared to 66.9% for INESSS. Of the 275 recommendations 
